Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Encompass Health Corporation for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The investigation is prompted by allegations that Encompass's for-profit hospitals perform below average on key safety measures, as reported by The New York Times [6]. - Specific concerns include that Encompass owns facilities with significantly worse rates of potentially preventable readmissions, with 34 facilities rated poorly by Medicare [6]. Stock Impact - Following the publication of the allegations, Encompass's stock price dropped by $12.39, or 10.4%, closing at $107.28 per share on July 15, 2025, indicating a direct financial impact on investors [6].

Core Viewpoint - A class action lawsuit has been filed against Dow, Inc. for allegedly making materially false and misleading statements regarding its business operations and financial condition during the specified class period from January 30, 2025, to July 23, 2025 [1][7]. Allegation Details - Defendants are accused of overstating Dow's ability to manage macroeconomic and tariff-related challenges, as well as its financial flexibility to support dividends [3]. - The negative impacts of competitive pressures, declining global sales, and product oversupply on Dow's business were allegedly understated [3]. - Public statements made by the defendants were claimed to be materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Dow shares and experienced losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 28, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a recognized law firm that represents individual and institutional investors in various complex litigations across the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Fluor Corporation for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the specified class period from February 18, 2025, to July 31, 2025 [3][7]. Allegation Details - The complaint alleges that Fluor's management failed to disclose significant cost increases related to major projects, including the Gordie Howe, I-635/LBJ, and I-35 projects, due to subcontractor design errors, price increases, and scheduling delays [3]. - It is claimed that these issues, along with reduced capital spending from customers and economic uncertainty, were likely to have a significant negative impact on Fluor's business and financial results [3]. - The financial guidance provided by Fluor for FY 2025 is described as unreliable and unrealistic, with an overstated effectiveness of the company's risk mitigation strategy and an understated impact of economic uncertainty [3]. Next Steps - Investors who purchased Fluor shares and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information regarding their rights and potential claims [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is November 14, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts in the United States [5].

Core Viewpoint - A class action lawsuit has been filed against Snap, Inc. for allegedly providing misleading statements regarding its advertising revenue growth, leading to significant losses for investors during the specified class period [8]. Allegation Details - The lawsuit claims that Snap's management made overly positive statements while concealing material adverse facts about the company's advertising revenue growth rate, which dropped from 9% in Q1 to only 1% in April [8]. - Snap's financial results announced on August 5, 2025, revealed a deceleration in advertising revenue growth, attributed to issues with their ad platform and other factors [8]. Stock Price Impact - Following the announcement of disappointing financial results, Snap's stock price fell from $9.39 per share on August 5, 2025, to $7.78 per share on August 6, 2025, marking a decline of approximately 17.15% in one day [8]. Next Steps for Investors - Investors who purchased Snap shares during the class period and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information and to discuss their legal rights [4][8].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PubMatic (PUBM) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in PubMatic between February 27, 2025 and August 11, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- What’s Happenin ...

Core Points - A class action lawsuit has been filed against Unicycive Therapeutics, Inc. for alleged misrepresentations regarding its New Drug Application for oxylanthanum carbonate [7] - The lawsuit covers investors who purchased Unicycive securities between March 29, 2024, and June 27, 2025, with a deadline of October 14, 2025, to apply as lead plaintiff [7] - The complaint alleges that Unicycive overstated its readiness to meet FDA manufacturing compliance requirements, which led to significant stock price declines following negative FDA inspections [7] Allegation Details - The lawsuit claims that Unicycive assured investors of its ability to satisfy FDA requirements but failed to disclose deficiencies identified by the FDA at a third-party manufacturing vendor [7] - Following the announcement of these deficiencies on June 10, 2025, Unicycive's stock price fell over 40% [7] - On June 30, 2025, the FDA issued a Complete Response Letter for the NDA, resulting in a further stock price decline of almost 30%, closing at $4.77 per share [7] Next Steps - Investors who suffered losses and wish to discuss their legal rights are encouraged to contact Bragar Eagel & Squire, P.C. for more information [4][8] - The law firm represents individual and institutional investors in complex litigation across the United States [5]

Core Viewpoint - A class action lawsuit has been filed against Snap, Inc. for allegedly providing misleading statements regarding its advertising revenue growth, leading to significant losses for investors during the specified class period [8]. Allegation Details - The lawsuit claims that Snap's management made overly positive statements while concealing material adverse facts about the company's advertising revenue growth rate, which dropped from 9% in Q1 to only 1% in April [8]. - Snap's financial results announced on August 5, 2025, revealed a deceleration in advertising revenue growth, attributed to issues with their ad platform and other factors [8]. Stock Price Impact - Following the announcement of disappointing financial results, Snap's stock price fell from $9.39 per share on August 5, 2025, to $7.78 per share on August 6, 2025, marking a decline of approximately 17.15% in one day [8]. Next Steps for Investors - Investors who purchased Snap shares during the class period and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 20, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across the United States [5].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In KinderCare (KLC) To Contact Him Directly To Discuss Their Options If you purchased or acquired IPOs in KinderCare and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally reco ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In KBR To Contact Him Directly To Discuss Their Options If you purchased or acquired KBR securities between May 6, 2025 and June 19, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 01, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P. ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In CarMax (KMX) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in CarMax and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar Eagel & Squire, P.C., a nationally recognized ...